According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in ...

Biological E Ltd. has partnered with Jiangsu Recbio Technology to commercialize the latter's HPV9 vaccine, REC603, in India.

Biological E will begin large-scale manufacturing of the HPV9 vaccine once the Technology transfer is completed.

Jiangsu Recbio Technology Company Limited, a leading Chinese biopharmaceutical company, today announced they have entered into a licensing cooperation agreement, and commenced the technology transfer ...

According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF & PAHO tenders in other markets.

As we enjoy the long, hot summer, we think of long strolls on the beach and the feel of sand through our toes. We never think of the dangers that ...

Biological E. to produce Recbio's HPV9 vaccine in India, expanding global access to cervical cancer prevention.

Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

BE to produce and commercialise Recbio's nine-valent HPV vaccine in India and global markets, including participation in ...

The implementation of these three key pillars — vaccination, screening, and treatment — are critical in eliminating cervical ...

As the waters off England, Ireland, Wales and even as far north as Scotland get warmer, they become a more favourable ...